ATE.v/ATBPF -.01 to C$.26 Here an overview of Antibe by Zacks from last year with a valuation based on getting a partner to advance phase III and commercialize the drug. Zacks gives it a 50% chance of approval. http://s1.q4cdn.com/460208960/files/News/2017/Sept-5-2017_V.ATE_Bautz.pdf